Aclaris Therapeutics financials
$5.28−2.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $2.0M | $1.3M | $3.3M | $1.8M | $1.5M | $9.2M | $4.3M | $2.8M | $2.4M | $17.6M | $9.3M |
| Gross profit | $1.4M | $1.6M | $763.0K | $2.8M | $1.3M | $949.0K | $8.5M | $3.7M | $2.1M | $1.6M | $16.8M | $8.4M |
| Gross margin | 86.6% | 80.2% | 58.9% | 83.7% | 71.0% | 65.2% | 92.3% | 85.0% | 77.4% | 66.3% | 95.9% | 90.9% |
| Operating income | -$24.2M | -$22.2M | -$22.7M | -$17.1M | -$18.4M | -$17.8M | -$99.7M | -$10.5M | -$12.9M | -$18.9M | -$4.0M | -$31.6M |
| Net income | -$21.5M | -$19.8M | -$19.8M | -$14.6M | -$15.4M | -$15.1M | -$96.6M | -$7.6M | -$11.0M | -$16.9M | -$1.5M | -$29.3M |
| Net margin | −1320.1% | −993.2% | −1528.6% | −443.0% | −868.3% | −1036.8% | −1048.2% | −174.6% | −397.2% | −706.5% | −8.5% | −315.2% |
| Diluted EPS | $-0.15 | $-0.15 | $-0.16 | $-0.12 | $-0.13 | $-0.12 | $-1.01 | $-0.11 | $-0.15 | $-0.24 | $-0.02 | $-0.41 |
| EBITDA | -$24.1M | -$22.1M | -$22.2M | -$16.9M | -$18.3M | -$17.7M | -$100.8M | -$9.5M | -$12.4M | -$15.9M | -$30.1M | -$29.7M |
| Operating cash flow | -$19.8M | -$18.1M | -$13.1M | -$10.9M | -$10.0M | -$13.1M | -$8.9M | $22.0M | -$9.5M | -$23.6M | -$7.4M | -$26.3M |
| Free cash flow | -$19.9M | -$18.2M | -$13.2M | -$11.0M | -$10.0M | -$13.1M | -$8.9M | $22.0M | -$9.5M | -$23.8M | -$7.8M | -$26.3M |
| Diluted shares | 142.7M | 128.8M | 122.7M | 122.6M | 122.6M | 122.4M | 95.4M | 71.4M | 71.3M | 71.1M | 70.9M | 70.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.2M | $28.7M | $20.0M | $25.3M | $25.4M | $30.4M |
| Short-term investments | $72.4M | $76.8M | $70.8M | $70.7M | $74.4M | $75.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $179.7M | $198.7M | $160.5M | $175.5M | $189.1M | $198.1M |
| Total liabilities | $55.1M | $55.1M | $57.4M | $55.4M | $57.4M | $54.0M |
| Shareholders' equity | $124.6M | $143.6M | $103.1M | $120.1M | $131.7M | $144.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology